Xencor (XNCR) Operating Margin (2013 - 2026)
Xencor (XNCR) posted quarterly Operating Margin of 1724.14% for Q1 2026, down 159221.0% year-over-year from N/an in Q1 2025, and down 807.82% quarter-over-quarter from 189.92% in Q4 2025.
Powered by 
Analysis
Xencor (XNCR) Operating Margin (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Operating Margin for 14 consecutive years, with 1724.14% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin fell 159221.0% year-over-year to 1724.14%; the TTM figure through Mar 2026 stood at 217.93% (down 8673.0% YoY), while the FY2025 annual figure was 141.35%, up 2012.0% from the prior year.
- Operating Margin eased to 1724.14% in Q1 2026 per XNCR's latest filing, from 189.92% in the prior quarter.
- Across five years, Operating Margin topped out at 30.96% in Q1 2022 and bottomed at 1724.14% in Q1 2026.
- Historically, Operating Margin has averaged 242.2% across 5 years, with a median of 140.47% in 2022.
- Annual changes were most pronounced in 2025 — Operating Margin jumped 20978 bps — and 2026, when it tumbled 159221 bps.
- Xencor's Operating Margin stood at 197.1% in 2022, then jumped by 73 bps to 53.61% in 2023, then surged by 53 bps to 24.96% in 2024, then sank by 661 bps to 189.92% in 2025, then sank by 808 bps to 1724.14% in 2026.
- Business Quant data shows XNCR's Operating Margin at 1724.14% in Q1 2026, 189.92% in Q4 2025, and 226.29% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | -72.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -72.37% |
| Mar 31, 2026 | -1,724.14% |
| Dec 31, 2025 | -189.92% |
| Sep 30, 2025 | -226.29% |
| Jun 30, 2025 | -76.07% |
| Mar 31, 2025 | -131.93% |
| Dec 31, 2024 | -24.96% |
| Sep 30, 2024 | -310.17% |
| Jun 30, 2024 | -231.61% |
| Mar 31, 2024 | -341.71% |
| Dec 31, 2023 | -53.67% |
| Sep 30, 2023 | -30.86% |
| Jun 30, 2023 | -57.11% |
| Mar 31, 2023 | -319.71% |
| Dec 31, 2022 | -197.19% |
| Sep 30, 2022 | -140.47% |
| Jun 30, 2022 | -92.72% |
| Mar 31, 2022 | 30.95% |
| Dec 31, 2021 | 59.51% |
| Sep 30, 2021 | -209.64% |